Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2014; 5(4): 576-587
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.576
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.576
Review of the current targeted therapies for non-small-cell lung cancer
Kim-Son H Nguyen, Joel W Neal, Heather Wakelee, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States
Author contributions: All authors contributed equally to this paper.
Correspondence to: Heather Wakelee, MD, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States. hwakelee@stanford.edu
Telephone: +1-650-7367221 Fax: +1-650-7243697
Received: February 10, 2014
Revised: May 7, 2014
Accepted: May 28, 2014
Published online: October 10, 2014
Revised: May 7, 2014
Accepted: May 28, 2014
Published online: October 10, 2014
Core Tip
Core tip: The development of oncogene-directed targeted therapies has significantly changed the treatment of non-small-cell lung cancer. We review the data demonstrating efficacy of small-molecule tyrosine kinase inhibitors against epidermal growth factor receptor, anaplastic lymphoma kinase, ROS1, and other oncogenes. We also discuss the challenge of acquired resistance to these therapies and review promising agents which may overcome resistance.